[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Jonathan Cheng @JChengWSJ on x 85.9K followers
Created: 2025-07-02 01:53:10 UTC
“Ten years ago, what we saw coming out of China were more follow-on, similar drugs, less differentiation. What we are seeing today is fundamentally different: first-in-class, best-in-class,” Gilead Sciences’ CFO, Andrew Dickinson, said in January.
XXXXX engagements
Related Topics china gilead sciences stocks healthcare